Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study

Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The FOREST-HCM CMR Sub-study

Increase in HCM-Related Economic Burden Due to Atrial Fibrillation in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Analysis of 9490 Patients

An Evidence Gap Analysis of the Epidemiology and Burden of Obstructive Hypertrophic Cardiomyopathy

Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design

Logistic and Economic Burden of Non-Obstructive Hypertrophic Cardiomyopathy – Results From Medical and Pharmacy Claims Data

Healthcare Resource Utilization and Economic Burden Due to Atrial Fibrillation in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Real-World Analysis of 2016-2021 Claims Data

Acute Treatment With Aficamten Rescues Contractile Function in a Myopod® Engineered Heart Tissue Model of Hypertrophic Cardiomyopathy

Differences in Healthcare Resource Use and Cost by Treatment Choice Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Real-World Analysis of 2016-2021 Claims Data

A Phase 3 Randomized Controlled Trial Comparing Aficamten Vs Metoprolol In Patients With Symptomatic Hypertrophic Cardiomyopathy And Left Ventricular Outflow Tract Obstruction